# Toshihiko Doi

Source: https://onco.cc/people/doi-toshihiko/  
OnCo record `doi-toshihiko` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.

## Summary

Toshihiko Doi is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital East in Japan. He runs one of Asia's most productive phase 1 units and led the first-in-human study of DS-8201, the Daiichi Sankyo antibody-drug conjugate now known as trastuzumab deruxtecan, along with numerous other first-in-class studies in solid tumours. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in patients with advanced breast and gastric or gastro-oesophageal tumours. His interests are phase 1 trials, drug development, gastrointestinal oncology and antibody-drug conjugates. He also directs National Cancer Center Hospital East in Kashiwa, one of the main sites for first-in-human oncology trials in Japan, and led pivotal work on trastuzumab deruxtecan and trifluridine/tipiracil in gastric cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Also known as: toshihiko-doi
- Tags: leadership; clinician-scientist; gastric cancer; drug development
- Role: Director, Department of Experimental Therapeutics, National Cancer Center Hospital East
- Specialisms: Phase 1 trials; Drug development; Gastrointestinal oncology; Antibody-drug conjugates; Gastric cancer

## Sources

- National Cancer Center Hospital East: https://www.ncc.go.jp/en/ncce/index.html
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201
- Hospital director greeting: https://www.ncc.go.jp/en/ncce/about/greeting/index.html

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- institutions: [National Cancer Center Hospital](https://onco.cc/institutions/ncc-japan/), [National Cancer Center Hospital East](https://onco.cc/institutions/ncc-hospital-east/)

---
JSON: https://onco.cc/api/v1/entities/doi-toshihiko.json